These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

685 related articles for article (PubMed ID: 31674729)

  • 1. Quantitative Systems Pharmacology for Neuroscience Drug Discovery and Development: Current Status, Opportunities, and Challenges.
    Geerts H; Wikswo J; van der Graaf PH; Bai JPF; Gaiteri C; Bennett D; Swalley SE; Schuck E; Kaddurah-Daouk R; Tsaioun K; Pelleymounter M
    CPT Pharmacometrics Syst Pharmacol; 2020 Jan; 9(1):5-20. PubMed ID: 31674729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative systems pharmacology as an extension of PK/PD modeling in CNS research and development.
    Geerts H; Spiros A; Roberts P; Carr R
    J Pharmacokinet Pharmacodyn; 2013 Jun; 40(3):257-65. PubMed ID: 23338980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [An introduction to QSP modeling for pharmacologists].
    Sayama H; Nagasaka Y; Tabata K
    Nihon Yakurigaku Zasshi; 2019; 154(3):143-150. PubMed ID: 31527365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Translational Quantitative Systems Pharmacology in Drug Development: from Current Landscape to Good Practices.
    Bai JPF; Earp JC; Pillai VC
    AAPS J; 2019 Jun; 21(4):72. PubMed ID: 31161268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CNS drug development - lost in translation?
    Talevi A; Bellera CL; Di Ianni M; Gantner M; Bruno-Blanch LE; Castro EA
    Mini Rev Med Chem; 2012 Sep; 12(10):959-70. PubMed ID: 22420574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integration not isolation: arguing the case for quantitative and systems pharmacology in drug discovery and development.
    Agoram BM; Demin O
    Drug Discov Today; 2011 Dec; 16(23-24):1031-6. PubMed ID: 22020181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bundling arrows: improving translational CNS drug development by integrated PK/PD-metabolomics.
    van den Brink WJ; Hankemeier T; van der Graaf PH; de Lange ECM
    Expert Opin Drug Discov; 2018 Jun; 13(6):539-550. PubMed ID: 29519169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent applications of quantitative systems pharmacology and machine learning models across diseases.
    Aghamiri SS; Amin R; Helikar T
    J Pharmacokinet Pharmacodyn; 2022 Feb; 49(1):19-37. PubMed ID: 34671863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multitarget drug discovery projects in CNS diseases: quantitative systems pharmacology as a possible path forward.
    Geerts H; Kennis L
    Future Med Chem; 2014; 6(16):1757-69. PubMed ID: 25574530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tools in the Design of Therapeutic Drugs for CNS Disorders: An up-to-date Review.
    Sahu JK; Mishra AK
    Curr Mol Pharmacol; 2018; 11(4):270-278. PubMed ID: 30129422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Applications of Quantitative Systems Pharmacology in Model-Informed Drug Discovery: Perspective on Impact and Opportunities.
    Bradshaw EL; Spilker ME; Zang R; Bansal L; He H; Jones RDO; Le K; Penney M; Schuck E; Topp B; Tsai A; Xu C; Nijsen MJMA; Chan JR
    CPT Pharmacometrics Syst Pharmacol; 2019 Nov; 8(11):777-791. PubMed ID: 31535440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proceedings of the 2013 CINP summit: innovative partnerships to accelerate CNS drug discovery for improved patient care.
    Phillips AG; Hongaard-Andersen P; Moscicki RA; Sahakian B; Quirion R; Krishnan KR; Race T
    Int J Neuropsychopharmacol; 2014 Dec; 18(3):. PubMed ID: 25542690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative Systems Pharmacology for Rare Disease Drug Development.
    Bai JP; Wang J; Zhang Y; Wang L; Jiang X
    J Pharm Sci; 2023 Sep; 112(9):2313-2320. PubMed ID: 37422281
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Moreno MJ; Ling B; Stanimirovic DB
    Expert Opin Drug Discov; 2020 Aug; 15(8):903-915. PubMed ID: 32396023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulatory-accepted drug development tools are needed to accelerate innovative CNS disease treatments.
    Arnerić SP; Kern VD; Stephenson DT
    Biochem Pharmacol; 2018 May; 151():291-306. PubMed ID: 29410157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CNS Drug Development, Lessons Learned, Part 4: The Role of Brain Circuitry and Genes-Tasimelteon as an Example.
    Preskorn SH
    J Psychiatr Pract; 2017 Nov; 23(6):425-430. PubMed ID: 29303950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuronal Circuit-Based Computer Modeling as a Phenotypic Strategy for CNS R&D.
    Geerts H; Barrett JE
    Front Neurosci; 2019; 13():723. PubMed ID: 31379482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Opportunities in systems biology to discover mechanisms and repurpose drugs for CNS diseases.
    Mei H; Xia T; Feng G; Zhu J; Lin SM; Qiu Y
    Drug Discov Today; 2012 Nov; 17(21-22):1208-16. PubMed ID: 22750722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Applications of imaging biomarkers in the early clinical development of central nervous system therapeutic agents.
    Cole PE; Schwarz AJ; Schmidt ME
    Clin Pharmacol Ther; 2012 Feb; 91(2):315-20. PubMed ID: 22218072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Towards the virtual human patient. Quantitative Systems Pharmacology in Alzheimer's disease.
    Geerts H; Spiros A; Roberts P; Carr R
    Eur J Pharmacol; 2017 Dec; 817():38-45. PubMed ID: 28583429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.